SR One Capital Management LP Purchases New Shares in Oculis Holding AG $OCS

Key Points

• SR One Capital Management LP has purchased 322,500 shares of Oculis Holding AG (NASDAQ:OCS), valued at approximately $6.14 million, making it the firm's 8th largest position.
• Chardan Capital has increased its price target for Oculis from $28.00 to $33.00, maintaining a "buy" rating as of May 9th.
• Oculis is currently trading around $17.90 with a market capitalization of $781.51 million and a price-to-earnings ratio of -6.78.

SR One Capital Management LP acquired a new stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 322,500 shares of the company's stock, valued at approximately $6,137,000. Oculis accounts for about 1.6% of SR One Capital Management LP's holdings, making the stock its 8th largest holding. SR One Capital Management LP owned 0.74% of Oculis as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Aberdeen Group plc lifted its stake in shares of Oculis by 24.1% during the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock worth $23,847,000 after purchasing an additional 243,695 shares during the period. Bank of America Corp DE lifted its position in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after buying an additional 10,667 shares during the period. Citadel Advisors LLC acquired a new stake in Oculis in the 4th quarter worth about $389,000. Geode Capital Management LLC grew its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Oculis during the 4th quarter valued at about $225,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Wall Street Analyst Weigh In

Separately, Chardan Capital raised their target price on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $35.33.

Oculis Stock Performance

Shares of NASDAQ:OCS traded down $0.40 during midday trading on Wednesday, hitting $17.55. 31,514 shares of the company's stock traded hands, compared to its average volume of 44,925. The firm's fifty day moving average price is $18.49 and its two-hundred day moving average price is $18.79. Oculis Holding AG has a twelve month low of $10.79 and a twelve month high of $23.08. The company has a market cap of $766.23 million, a PE ratio of -6.65 and a beta of 0.27.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.